Epizyme Inc Cmn Stk (EPZM) 7.24 $EPZM Epizyme t
Post# of 273258
Posted On: 09/02/2016 11:06:37 AM
Epizyme Inc Cmn Stk (EPZM) 7.24 $EPZM
Epizyme to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Sep 01, 5:30AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at three investor conferences in September:
EPZM: 7.24 (-0.07)
Epizyme Doses First Patient in Phase II Mesothelioma Study
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 8:25AM CDT
Epizyme (EPZM) dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss-of-function.
ADRO: 14.22 (unch), EPZM: 7.24 (-0.07), LLY: 76.79 (-0.44)
Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma
GlobeNewswire - Thu Aug 11, 5:30AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the first patient has been dosed in the Company's global phase 2 study evaluating tazemetostat, a first-in-class EZH2 inhibitor, for the treatment of adults with mesothelioma characterized by BAP1 loss-of-function.
EPZM: 7.24 (-0.07)
Epizyme (EPZM) Q2 Loss Lower than Expected, Costs to Rise
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:22AM CDT
Epizyme (EPZM) reported a loss of 49 cents per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 50 cents.
GERN: 2.77 (+0.04), EPZM: 7.24 (-0.07), GSK: 44.10 (+1.12)
Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 7:50AM CDT
Epizyme (EPZM) reported a narrower-than-expected second quarter loss of 49 cents per share.
EPZM: 7.24 (-0.07)
Epizyme Announces Second Quarter 2016 Financial Results and Progress Against Corporate Objectives
GlobeNewswire - Mon Aug 08, 5:30AM CDT
Company Updates Financial Guidance Extending Runway into At Least Second Quarter of 2018
EPZM: 7.24 (-0.07)
What's in Store for Epizyme (EPZM) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:43AM CDT
Epizyme (EPZM) is schedule to report second-quarter 2016 results on Aug 9 before the opening bell.
IPXL: 23.77 (-0.17), MYL: 40.89 (-1.03), EPZM: 7.24 (-0.07)
Epizyme to Report Second Quarter 2016 Financial Results on August 8, 2016 and Participate in Upcoming Wedbush PacGrow Healthcare Conference
GlobeNewswire - Mon Aug 01, 3:05PM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced today that management will host a conference call and audio webcast on Monday, August 8, 2016, at 8:30 a.m. Eastern Time to report business highlights and progress against the company's multi-year vision, along with second quarter 2016 financial results.
EPZM: 7.24 (-0.07)
Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 61.49 (+0.07), PFE: 34.79 (+0.11), EPZM: 7.24 (-0.07)
Epizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq(TM) (atezolizumab) for Treatment of Non-Hodgkin Lymphoma
BusinessWire - Wed Jun 22, 11:09AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct a clinical trial to investigate the anti-cancer effects of Epizyme's EZH2 inhibitor, tazemetostat, and Genentech's recently approved anti-PD-L1 cancer immunotherapy, Tecentriq(TM) (atezolizumab), when used in combination. The study will evaluate this combination regimen for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
EPZM: 7.24 (-0.07)
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 42.09 (-0.21), PFE: 34.79 (+0.11), EPZM: 7.24 (-0.07), BMY: 55.92 (-0.84)
Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting
BusinessWire - Sun Jun 19, 6:53AM CDT
--Four of five cohorts have now surpassed futility, including follicular lymphoma with EZH2 mutation; responses observed in all patient cohorts
EPZM: 7.24 (-0.07)
Earnings Estimates Moving Higher for Epizyme (EPZM): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:56AM CDT
Epizyme (EPZM) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
EPZM: 7.24 (-0.07)
Ardelyx Appoints Robert Bazemore to Its Board of Directors
PR Newswire - Tue Jun 07, 8:00AM CDT
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Robert Bazemore joined the Company's Board of Directors. Mr. Bazemore, who currently serves as President and Chief Executive Officer of Epizyme, Inc., brings with him broad experience in drug development and in navigating the challenges associated with preparing growing organizations for commercialization. Following the appointment of Mr. Bazemore to its Board of Directors, Ardelyx will have six independent board members.
EPZM: 7.24 (-0.07), ARDX: 10.33 (+0.01)
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
Ekta Bagri - Zacks Investment Research - Tue May 10, 1:29PM CDT
Epizyme, Inc. (EPZM) reported a loss of 41 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 47 cents and the year-ago loss of $1.75.
SHPG: 191.20 (+2.70), EPZM: 7.24 (-0.07), GSK: 44.10 (+1.12), CELG: 106.00 (-0.37)
Epizyme reports 1Q loss
Automated Insights - Mon May 09, 5:46AM CDT
CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Monday reported a loss of $22.9 million in its first quarter.
EPZM: 7.24 (-0.07)
Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision
BusinessWire - Mon May 09, 5:40AM CDT
--Conference call to be held today at 8:00 a.m. Eastern Time
EPZM: 7.24 (-0.07)
Epizyme Announces Collaboration with Lymphoma Study Association to Evaluate Combination of Tazemetostat with R-CHOP in Front-line Non-Hodgkin Lymphoma
BusinessWire - Mon May 09, 5:35AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has entered into a collaboration agreement with the Lymphoma Study Association (LYSA) to investigate the combination of tazemetostat with R-CHOP as a front-line treatment in patients with diffuse large B-cell lymphoma (DLBCL). LYSA is a premier cooperative group in France dedicated to clinical and translational research for lymphoma, and is certified by the French National Cancer Institute. Under the agreement, the phase 1b/2 trial will be jointly conducted with the Lymphoma Academic Research Organisation (LYSARC), the operational arm of LYSA.
EPZM: 7.24 (-0.07)
Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer
BusinessWire - Fri May 06, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as Chief Operating Officer. In this role, Mr. Ros will be responsible for directing and operationalizing Epizyme's launch readiness efforts for tazemetostat, and will report to Epizyme's President and Chief Executive Officer, Robert Bazemore.
EPZM: 7.24 (-0.07)
Epizyme to Present at Upcoming Investor Conferences
GlobeNewswire - Thu Sep 01, 5:30AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the Company will present at three investor conferences in September:
EPZM: 7.24 (-0.07)
Epizyme Doses First Patient in Phase II Mesothelioma Study
Zacks Equity Research - Zacks Investment Research - Mon Aug 15, 8:25AM CDT
Epizyme (EPZM) dosed the first patient in a phase II study on tazemetostat for the treatment of adults with mesothelioma, characterized by BAP1 loss-of-function.
ADRO: 14.22 (unch), EPZM: 7.24 (-0.07), LLY: 76.79 (-0.44)
Epizyme Doses First Patient in Global Phase 2 Study Evaluating Tazemetostat in Mesothelioma
GlobeNewswire - Thu Aug 11, 5:30AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced that the first patient has been dosed in the Company's global phase 2 study evaluating tazemetostat, a first-in-class EZH2 inhibitor, for the treatment of adults with mesothelioma characterized by BAP1 loss-of-function.
EPZM: 7.24 (-0.07)
Epizyme (EPZM) Q2 Loss Lower than Expected, Costs to Rise
Zacks Equity Research - Zacks Investment Research - Tue Aug 09, 8:22AM CDT
Epizyme (EPZM) reported a loss of 49 cents per share in the second quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 50 cents.
GERN: 2.77 (+0.04), EPZM: 7.24 (-0.07), GSK: 44.10 (+1.12)
Epizyme (EPZM) Posts Narrower-Than-Expected Loss in Q2
Zacks Equity Research - Zacks Investment Research - Mon Aug 08, 7:50AM CDT
Epizyme (EPZM) reported a narrower-than-expected second quarter loss of 49 cents per share.
EPZM: 7.24 (-0.07)
Epizyme Announces Second Quarter 2016 Financial Results and Progress Against Corporate Objectives
GlobeNewswire - Mon Aug 08, 5:30AM CDT
Company Updates Financial Guidance Extending Runway into At Least Second Quarter of 2018
EPZM: 7.24 (-0.07)
What's in Store for Epizyme (EPZM) this Earnings Season?
Zacks Equity Research - Zacks Investment Research - Wed Aug 03, 9:43AM CDT
Epizyme (EPZM) is schedule to report second-quarter 2016 results on Aug 9 before the opening bell.
IPXL: 23.77 (-0.17), MYL: 40.89 (-1.03), EPZM: 7.24 (-0.07)
Epizyme to Report Second Quarter 2016 Financial Results on August 8, 2016 and Participate in Upcoming Wedbush PacGrow Healthcare Conference
GlobeNewswire - Mon Aug 01, 3:05PM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, announced today that management will host a conference call and audio webcast on Monday, August 8, 2016, at 8:30 a.m. Eastern Time to report business highlights and progress against the company's multi-year vision, along with second quarter 2016 financial results.
EPZM: 7.24 (-0.07)
Epizyme Teams Up with Roche's Genentech for Tazemetostat
Zacks Equity Research - Zacks Investment Research - Thu Jun 23, 7:32AM CDT
Epizyme (EPZM) announced that it has entered into a collaboration agreement with Roche's (RHHBY) Genentech to evaluate tazemetostat, in combination Tecentriq.
ANIP: 61.49 (+0.07), PFE: 34.79 (+0.11), EPZM: 7.24 (-0.07)
Epizyme Initiates Collaboration on Combination Trial of Tazemetostat and Tecentriq(TM) (atezolizumab) for Treatment of Non-Hodgkin Lymphoma
BusinessWire - Wed Jun 22, 11:09AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical-stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, announced today it has entered into a collaboration agreement with Genentech, a member of the Roche Group, to conduct a clinical trial to investigate the anti-cancer effects of Epizyme's EZH2 inhibitor, tazemetostat, and Genentech's recently approved anti-PD-L1 cancer immunotherapy, Tecentriq(TM) (atezolizumab), when used in combination. The study will evaluate this combination regimen for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma.
EPZM: 7.24 (-0.07)
Epizyme Offers Early Data on Non-Hodgkin Lymphoma Drug
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 2:05PM CDT
Epizyme, Inc. (EPZM) reported encouraging preliminary data from its ongoing, global phase II trial on lead pipeline candidate, tazemetostat, at the American Society of Hematology Meeting on Lymphoma Biology.
ABT: 42.09 (-0.21), PFE: 34.79 (+0.11), EPZM: 7.24 (-0.07), BMY: 55.92 (-0.84)
Epizyme Reports Early Data from Global Phase 2 Trial of Tazemetostat in Non-Hodgkin Lymphoma at ASH Lymphoma Biology Meeting
BusinessWire - Sun Jun 19, 6:53AM CDT
--Four of five cohorts have now surpassed futility, including follicular lymphoma with EZH2 mutation; responses observed in all patient cohorts
EPZM: 7.24 (-0.07)
Earnings Estimates Moving Higher for Epizyme (EPZM): Time to Buy?
Zacks Equity Research - Zacks Investment Research - Thu Jun 09, 7:56AM CDT
Epizyme (EPZM) could be good choice for investors as it is seeing decent short-term momentum and positive earnings estimate revisions.
EPZM: 7.24 (-0.07)
Ardelyx Appoints Robert Bazemore to Its Board of Directors
PR Newswire - Tue Jun 07, 8:00AM CDT
Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on gastrointestinal and cardio-renal diseases, today announced that Robert Bazemore joined the Company's Board of Directors. Mr. Bazemore, who currently serves as President and Chief Executive Officer of Epizyme, Inc., brings with him broad experience in drug development and in navigating the challenges associated with preparing growing organizations for commercialization. Following the appointment of Mr. Bazemore to its Board of Directors, Ardelyx will have six independent board members.
EPZM: 7.24 (-0.07), ARDX: 10.33 (+0.01)
Epizyme (EPZM) Reports Narrower-than-Expected Q1 Loss
Ekta Bagri - Zacks Investment Research - Tue May 10, 1:29PM CDT
Epizyme, Inc. (EPZM) reported a loss of 41 cents per share in the first quarter of 2016, narrower than both the Zacks Consensus Estimate of a loss of 47 cents and the year-ago loss of $1.75.
SHPG: 191.20 (+2.70), EPZM: 7.24 (-0.07), GSK: 44.10 (+1.12), CELG: 106.00 (-0.37)
Epizyme reports 1Q loss
Automated Insights - Mon May 09, 5:46AM CDT
CAMBRIDGE, Mass. (AP) _ Epizyme Inc. (EPZM) on Monday reported a loss of $22.9 million in its first quarter.
EPZM: 7.24 (-0.07)
Epizyme Announces First Quarter 2016 Financial Results and Provides Update on Execution Against Multi-Year Company Vision
BusinessWire - Mon May 09, 5:40AM CDT
--Conference call to be held today at 8:00 a.m. Eastern Time
EPZM: 7.24 (-0.07)
Epizyme Announces Collaboration with Lymphoma Study Association to Evaluate Combination of Tazemetostat with R-CHOP in Front-line Non-Hodgkin Lymphoma
BusinessWire - Mon May 09, 5:35AM CDT
Epizyme, Inc. (NASDAQ:EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has entered into a collaboration agreement with the Lymphoma Study Association (LYSA) to investigate the combination of tazemetostat with R-CHOP as a front-line treatment in patients with diffuse large B-cell lymphoma (DLBCL). LYSA is a premier cooperative group in France dedicated to clinical and translational research for lymphoma, and is certified by the French National Cancer Institute. Under the agreement, the phase 1b/2 trial will be jointly conducted with the Lymphoma Academic Research Organisation (LYSARC), the operational arm of LYSA.
EPZM: 7.24 (-0.07)
Epizyme Continues to Build Senior Leadership Team with Appointment of Matthew Ros as Chief Operating Officer
BusinessWire - Fri May 06, 7:00AM CDT
Epizyme, Inc. (NASDAQ: EPZM), a clinical stage biopharmaceutical company creating novel epigenetic therapies for people with cancer, today announced that it has expanded its senior leadership team with the addition of Matthew Ros, who joins the company as Chief Operating Officer. In this role, Mr. Ros will be responsible for directing and operationalizing Epizyme's launch readiness efforts for tazemetostat, and will report to Epizyme's President and Chief Executive Officer, Robert Bazemore.
EPZM: 7.24 (-0.07)
(0)
(0)Scroll down for more posts ▼